u/old_account_2023

How fast was the escalation in that protocol?

That figure is from the obesity programme, and this thread is about the hepatic one.

Yes — a proposal with concrete wording gets discussed. A complaint about the rules in general does not.

no question is too basic here, that is the entire point of the board

Careful — that would make individual moderation cases public by default, which is worse for the person complaining.

It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.

Push back: handling advice from one compound does not transfer to another just because both are peptides.

Which phase and which arm are you quoting?

maintenance is where the logistics finally get boring, which is the point

search first, but a repeat question is not a crime

This is the answer. Everything else in the thread is elaboration on it.

Concentration is mass over volume, and a U-100 syringe reads 100 units per millilitre. Those two facts are the whole of the arithmetic this board keeps explaining.

Which endpoint — histological response, fibrosis improvement, or fat fraction?

Push back: handling advice from one compound does not transfer to another just because both are peptides.

I would not treat catalogue breadth as a quality signal. It is a business decision, not an analytical one.

a secretagogue and a fragment are not the same class of thing

glucagon agonism and energy expenditure is the mechanistic thread

The endpoint vocabulary, because you cannot read this literature without it.

Resolution of steatohepatitis without worsening of fibrosis and improvement in fibrosis without worsening of steatohepatitis are the two standard composite endpoints, both scored on biopsy by pathologists against a defined system. Liver fat fraction is an imaging surrogate that correlates imperfectly with histology.

A trial can move the surrogate substantially and the histological endpoint modestly. Both results are real; they answer different questions. Anybody quoting a response rate here should say which endpoint it refers to, and most summaries do not.

Body weight varies by a couple of kilos over days in stable people through fluid, glycogen and gut content. A range is not a trend.

Interval stretching changes the exposure profile: with a week-long half-life, moving to ten or twelve days lowers trough concentration more than it lowers average exposure. That is why appetite return is often the first thing noticed.

identity before purity, every time, for anything unusual

That method was developed for a different compound class and would not resolve the impurities you are asking about.

Disagree — that name refers to at least two different molecules depending on who is selling it. The thread needs to be specific.

Ordered under a name that turned out to cover two different molecules. Nobody’s fault but mine for not asking.

Agreed that thin testing here says something about the members, not about the material.

That is a range, not a trend. Two weigh-ins 3 days apart cannot distinguish them.

ask the dumb question, three other people are searching for it

MASH endpoints are histological, which is a much harder bar

Week 11 for me was completely flat and I was convinced something was wrong. It was not. Month two was where everything happened.

Asked for identity confirmation on an unusual line and got a mass spectrum with the theoretical mass alongside.

This is the rule for anything unusual. Identity before anything else.

bacteriostatic water has a preservative, sterile water does not

pens and vials are the same molecule with different logistics

A rule-change proposal needs replacement wording because that is what can be evaluated. Without it there is nothing to compare against the current text.